You are here:
URINARY BIOMARKER INTERPRETATION USING PHARMACOKINETIC MODELS
Citation:
OKINO, M. S., C. B. THOMPSON, F. W. POWER, R. TORNERO-VELEZ, A. TSANG, J. N. BLANCATO, AND C. C. DARY. URINARY BIOMARKER INTERPRETATION USING PHARMACOKINETIC MODELS. Presented at International Council of Chemistry Associations Workshop, Minneapolis, MN, July 26 - 27, 2006.
Impact/Purpose:
Objectives for this task include the following:
o Investigate the current research on biomarkers of exposure for humans (ILSI documents).
o Develop better measurement methods and procedures for collecting biomarkers of exposure in human research studies.
o Conduct advanced statistical analyses on existing urinary biomarker data generated from EPA funded studies.
o Identify and provide valuable data inputs for modelers in their toxicokinetic and exposure models.
o Use modeling tools to understand the exposures of humans to chemicals related to biomarkers of exposure.
o Form a collaborative partnership with CDC to develop analytical methods for chemicals used as biomarkers of exposure in humans.
o Develop statistical methods and models to assess human exposures to chemicals of concern.
Description:
The issues involved with applying PBPK models in urinary biomarker interpretation were presented. Example scenarios were modeled, and absorbed doses were estimated for selected participants from a field study to illustrate the applicability and limitations of the methods.